CD40CR-Rezeptor und Liganden dafür
The present invention relates to an antibody that binds an antigen that: (a) is present on activated but not resting helper T-cells; (b) has the same molecular weight as a protein precipitated by a CD40-immunoglobulin (CD40-Ig) fusion protein, the CD40-Ig comprising the extracellular domain of a CD4...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Format: | Patent |
| Sprache: | ger |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | ARUFFO, ALEJANDRO A LEDBETTER, JEFFREY A STAMENKOVIC, IVAN NOELL, RANDOLPH |
| description | The present invention relates to an antibody that binds an antigen that:
(a) is present on activated but not resting helper T-cells;
(b) has the same molecular weight as a protein precipitated by a CD40-immunoglobulin (CD40-Ig) fusion protein, the CD40-Ig comprising the extracellular domain of a CD40 protein having the amino acid sequence of SEQ ID NO:2 and an extracellular domain at the site of fusion having the amino acid sequence of SEQ ID NO:3; and
(c) is pre-cleared by precipitation with the CD40-Ig;
wherein the antibody is capable of blocking binding of the CD40-Ig to activated helper T-cells and is capable of inhibiting helper T-cell induction of B-cell activation. The present invention also relates to pharmaceutical compositions comprising said antibody and the use of said antibody for therapeutic purposes, e. g. for inhibiting immunoglobulin production, inhibiting activation of B-cells and for treating disorders associated with B-cell activation, allergy, e. g.-anaphylaxis, autoimmune conditions, e. g. drug-induced lupus, systemic lupus erythematosus, adult rheumatoid arthritis, juvenile rheumatoid arthritis, scleroderma or Sjogren's syndrome, or viral diseases that involve B-cells, e. g. Epstein-Barr infection or retroviral infections such as infections with the human immunodeficiency virus. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_DE69333591TT2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>DE69333591TT2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_DE69333591TT23</originalsourceid><addsrcrecordid>eNrjZFB2djExcA7SDUqtSi0oyS9SKM1LUfDJTE_MS0nNU0hJTDu8p4iHgTUtMac4lRdKczMoubmGOHvophbkx6cWFyQmp-allsS7uJpZGhsbm1oahoQYGROlCADvNCbJ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>CD40CR-Rezeptor und Liganden dafür</title><source>esp@cenet</source><creator>ARUFFO, ALEJANDRO A ; LEDBETTER, JEFFREY A ; STAMENKOVIC, IVAN ; NOELL, RANDOLPH</creator><creatorcontrib>ARUFFO, ALEJANDRO A ; LEDBETTER, JEFFREY A ; STAMENKOVIC, IVAN ; NOELL, RANDOLPH</creatorcontrib><description>The present invention relates to an antibody that binds an antigen that:
(a) is present on activated but not resting helper T-cells;
(b) has the same molecular weight as a protein precipitated by a CD40-immunoglobulin (CD40-Ig) fusion protein, the CD40-Ig comprising the extracellular domain of a CD40 protein having the amino acid sequence of SEQ ID NO:2 and an extracellular domain at the site of fusion having the amino acid sequence of SEQ ID NO:3; and
(c) is pre-cleared by precipitation with the CD40-Ig;
wherein the antibody is capable of blocking binding of the CD40-Ig to activated helper T-cells and is capable of inhibiting helper T-cell induction of B-cell activation. The present invention also relates to pharmaceutical compositions comprising said antibody and the use of said antibody for therapeutic purposes, e. g. for inhibiting immunoglobulin production, inhibiting activation of B-cells and for treating disorders associated with B-cell activation, allergy, e. g.-anaphylaxis, autoimmune conditions, e. g. drug-induced lupus, systemic lupus erythematosus, adult rheumatoid arthritis, juvenile rheumatoid arthritis, scleroderma or Sjogren's syndrome, or viral diseases that involve B-cells, e. g. Epstein-Barr infection or retroviral infections such as infections with the human immunodeficiency virus.</description><edition>7</edition><language>ger</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; ENZYMOLOGY ; FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2005</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20050901&DB=EPODOC&CC=DE&NR=69333591T2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20050901&DB=EPODOC&CC=DE&NR=69333591T2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>ARUFFO, ALEJANDRO A</creatorcontrib><creatorcontrib>LEDBETTER, JEFFREY A</creatorcontrib><creatorcontrib>STAMENKOVIC, IVAN</creatorcontrib><creatorcontrib>NOELL, RANDOLPH</creatorcontrib><title>CD40CR-Rezeptor und Liganden dafür</title><description>The present invention relates to an antibody that binds an antigen that:
(a) is present on activated but not resting helper T-cells;
(b) has the same molecular weight as a protein precipitated by a CD40-immunoglobulin (CD40-Ig) fusion protein, the CD40-Ig comprising the extracellular domain of a CD40 protein having the amino acid sequence of SEQ ID NO:2 and an extracellular domain at the site of fusion having the amino acid sequence of SEQ ID NO:3; and
(c) is pre-cleared by precipitation with the CD40-Ig;
wherein the antibody is capable of blocking binding of the CD40-Ig to activated helper T-cells and is capable of inhibiting helper T-cell induction of B-cell activation. The present invention also relates to pharmaceutical compositions comprising said antibody and the use of said antibody for therapeutic purposes, e. g. for inhibiting immunoglobulin production, inhibiting activation of B-cells and for treating disorders associated with B-cell activation, allergy, e. g.-anaphylaxis, autoimmune conditions, e. g. drug-induced lupus, systemic lupus erythematosus, adult rheumatoid arthritis, juvenile rheumatoid arthritis, scleroderma or Sjogren's syndrome, or viral diseases that involve B-cells, e. g. Epstein-Barr infection or retroviral infections such as infections with the human immunodeficiency virus.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2005</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZFB2djExcA7SDUqtSi0oyS9SKM1LUfDJTE_MS0nNU0hJTDu8p4iHgTUtMac4lRdKczMoubmGOHvophbkx6cWFyQmp-allsS7uJpZGhsbm1oahoQYGROlCADvNCbJ</recordid><startdate>20050901</startdate><enddate>20050901</enddate><creator>ARUFFO, ALEJANDRO A</creator><creator>LEDBETTER, JEFFREY A</creator><creator>STAMENKOVIC, IVAN</creator><creator>NOELL, RANDOLPH</creator><scope>EVB</scope></search><sort><creationdate>20050901</creationdate><title>CD40CR-Rezeptor und Liganden dafür</title><author>ARUFFO, ALEJANDRO A ; LEDBETTER, JEFFREY A ; STAMENKOVIC, IVAN ; NOELL, RANDOLPH</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_DE69333591TT23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>ger</language><creationdate>2005</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>ARUFFO, ALEJANDRO A</creatorcontrib><creatorcontrib>LEDBETTER, JEFFREY A</creatorcontrib><creatorcontrib>STAMENKOVIC, IVAN</creatorcontrib><creatorcontrib>NOELL, RANDOLPH</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>ARUFFO, ALEJANDRO A</au><au>LEDBETTER, JEFFREY A</au><au>STAMENKOVIC, IVAN</au><au>NOELL, RANDOLPH</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>CD40CR-Rezeptor und Liganden dafür</title><date>2005-09-01</date><risdate>2005</risdate><abstract>The present invention relates to an antibody that binds an antigen that:
(a) is present on activated but not resting helper T-cells;
(b) has the same molecular weight as a protein precipitated by a CD40-immunoglobulin (CD40-Ig) fusion protein, the CD40-Ig comprising the extracellular domain of a CD40 protein having the amino acid sequence of SEQ ID NO:2 and an extracellular domain at the site of fusion having the amino acid sequence of SEQ ID NO:3; and
(c) is pre-cleared by precipitation with the CD40-Ig;
wherein the antibody is capable of blocking binding of the CD40-Ig to activated helper T-cells and is capable of inhibiting helper T-cell induction of B-cell activation. The present invention also relates to pharmaceutical compositions comprising said antibody and the use of said antibody for therapeutic purposes, e. g. for inhibiting immunoglobulin production, inhibiting activation of B-cells and for treating disorders associated with B-cell activation, allergy, e. g.-anaphylaxis, autoimmune conditions, e. g. drug-induced lupus, systemic lupus erythematosus, adult rheumatoid arthritis, juvenile rheumatoid arthritis, scleroderma or Sjogren's syndrome, or viral diseases that involve B-cells, e. g. Epstein-Barr infection or retroviral infections such as infections with the human immunodeficiency virus.</abstract><edition>7</edition><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | ger |
| recordid | cdi_epo_espacenet_DE69333591TT2 |
| source | esp@cenet |
| subjects | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE |
| title | CD40CR-Rezeptor und Liganden dafür |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T04%3A21%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=ARUFFO,%20ALEJANDRO%20A&rft.date=2005-09-01&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EDE69333591TT2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |